This site is intended for healthcare professionals only
LoginRegister
Pfizer files second lawsuit against Metsera, its controlling stockholders, Novo NordiskViatris unit Mylan, former President Rajiv Malik cleared in US Department of Justice generic drug...
Setback to Sun Pharma as Fibromun, Nidlegy Trials Miss Key Endpoints in Cancer StudiesSun Pharma pulled up by USFDA for manufacturing issues at Dadra facility
Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance FailuresWebsite unlawfully selling versions of Novo Nordisk weight loss drugs gets USFDA warning
Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus DealEli Lilly Company Gets CDSCO Panel Nod To Import, Market Antidiabetic drug Tirzepatide for chronic...
Sanofis Sarclisa Gets EMA Nod for Subcutaneous On-Body Injector VersionDupixent approved in EU as targeted therapy for COPD: Sanofi, Regeneron Pharma
Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus DealEli Lilly Kisunla gets USFDA okay for early Symptomatic Alzheimer's Disease
CDSCO Clears AstraZenecas Imfinzi (Durvalumab) for Additional Cancer Indication in IndiaLynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca
USFDA Flags Compliance Issues at Novo Nordisks New Jersey FacilityNovo Nordisk Gets CDSCO Panel Nod To Import, Market Insulin Icodec to treat diabetes mellitus in...
Marksans Pharma UK arm Relonchem gets marketing nod for high BP drugMarksans Pharma arm bags UKMHRA marketing authorization for Rasagiline Relonchem, Olmesartan tablets
Sanofis Sarclisa Gets EMA Nod for Subcutaneous On-Body Injector VersionSanofi plans up to USD 1.6 billion investment in Germany: Handelsblatt
CDSCO Clears AstraZenecas Imfinzi (Durvalumab) for Additional Cancer Indication in IndiaSipavibart EMA regulatory submission accepted under accelerated assessment for COVID 19 prevention:...
AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia TreatmentCDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab
X